Legend Biotech Corporation ADR
Legend Biotech Corporation ADR is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing cell therapies for oncology and other serious diseases. The company’s work centers on advanced immunotherapy platforms, including chimeric antigen receptor T-cell approaches and other cellular therapies designed to target hard-to-treat cancers. Its portfolio is led by CARVYKTI, a BCMA-directed CAR-T therapy used in multiple myeloma, and it also supports additional investigational cell therapy programs across hematologic and solid tumor settings. Legend Biotech serves patients and healthcare providers through a global footprint spanning the United States, China, and Europe, combining research, manufacturing, and commercialization capabilities within a single operational model. As an ADR, Legend Biotech Corporation ADR provides market access to a company positioned at the intersection of biotechnology innovation and specialty cancer treatment.
$18.48
-$1.32 (-6.67%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-13.27% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 64.0% YoY with margins expanding 35.1pp.
Negative free cash flow of -$129M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.27B
▲ +64.0% YoY
Net Income (TTM)
-$92M
▼ -67.7% YoY
Op. Margin
-4.42%
▲ +35.1pp YoY
ROIC
-7.68%
▲ +8.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$122M
▲ +18.6% YoY
Op. Cash Flow (TTM)
-$89M
▼ -43.5% YoY
Net Debt
-$535M
Net Cash Position
Cash & Equiv.
$949M
3Y CAGR: +106.4%
Continue Research
Is Legend Biotech Corporation ADR (LEGN) overvalued?
Legend Biotech Corporation ADR (LEGN)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Legend Biotech Corporation ADR scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Legend Biotech Corporation ADR a high-quality business?+
Legend Biotech Corporation ADR scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -4.4% operating margin and a -7.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Legend Biotech Corporation ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh LEGN's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.